These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22719025)

  • 1. Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence.
    Spoladore R; Maron MS; D'Amato R; Camici PG; Olivotto I
    Eur Heart J; 2012 Jul; 33(14):1724-33. PubMed ID: 22719025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives.
    Ammirati E; Contri R; Coppini R; Cecchi F; Frigerio M; Olivotto I
    Eur J Heart Fail; 2016 Sep; 18(9):1106-18. PubMed ID: 27109894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertrophic cardiomyopathy: The need for randomized trials.
    Olivotto I; Tomberli B; Spoladore R; Mugelli A; Cecchi F; Camici PG
    Glob Cardiol Sci Pract; 2013; 2013(3):243-8. PubMed ID: 24689025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy and risk-stratification in hypertrophic cardiomyopathy--a current survey].
    Reith S; Klues HG
    Z Kardiol; 2003 Apr; 92(4):283-93. PubMed ID: 12707787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy.
    Sherrid MV; Arabadjian M
    Prog Cardiovasc Dis; 2012; 54(6):483-92. PubMed ID: 22687589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular targets and novel pharmacological options to prevent myocardial hypertrophic remodeling].
    Coppini R; Ferrantini C; Poggesi C; Mugelli A; Olivotto I
    G Ital Cardiol (Rome); 2016 Mar; 17(3):189-96. PubMed ID: 27029877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development of familial hypertrophic cardiomyopathy: from mutation to bedside.
    Brouwer WP; van Dijk SJ; Stienen GJ; van Rossum AC; van der Velden J; Germans T
    Eur J Clin Invest; 2011 May; 41(5):568-78. PubMed ID: 21158848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug therapy of atrial fibrillation].
    Fazekas T; Csanádi Z; Varró A
    Orv Hetil; 2003 Jun; 144(24):1199-206. PubMed ID: 12866149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk stratification in hypertrophic cardiomyopathy: time for renewal?
    Pacileo G; Salerno G; Gravino R; Calabrò R; Elliott PM
    J Cardiovasc Med (Hagerstown); 2013 May; 14(5):319-25. PubMed ID: 22885536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy for the treatment of obstructive hypertrophic cardiomyopathy.
    Spoladore R; Fragasso G; Pannone L; Slavich M; Margonato A
    Expert Opin Pharmacother; 2020 Feb; 21(2):233-242. PubMed ID: 31893930
    [No Abstract]   [Full Text] [Related]  

  • 11. [Management of refractory symptoms in hypertrophic cardiomyopathy with restrictive pathophysiology: novel perspectives for ranolazine].
    Tomberli B; Girolami F; Coppini R; Ferrantini C; Rossi A; Cecchi F; Olivotto I
    G Ital Cardiol (Rome); 2012 Apr; 13(4):297-303. PubMed ID: 22495647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Atrial fibrillation in hypertrophic cardiomyopathy: determinants, clinical course and management].
    Olivotto I; DiDonna P; Baldi M; Sgalambro A; Maron BJ; Cecchi F
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Apr; 37(4):303-7. PubMed ID: 19791463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy.
    Maron MS; Finley JJ; Bos JM; Hauser TH; Manning WJ; Haas TS; Lesser JR; Udelson JE; Ackerman MJ; Maron BJ
    Circulation; 2008 Oct; 118(15):1541-9. PubMed ID: 18809796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does myectomy convey survival benefit in hypertrophic cardiomyopathy?
    Woo A; Rakowski H
    Heart Fail Clin; 2007 Jul; 3(3):275-88. PubMed ID: 17723936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction.
    Maron MS; Olivotto I; Zenovich AG; Link MS; Pandian NG; Kuvin JT; Nistri S; Cecchi F; Udelson JE; Maron BJ
    Circulation; 2006 Nov; 114(21):2232-9. PubMed ID: 17088454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertrophic cardiomyopathy. Pathophysiology, diagnosis, and treatment.
    Popjes ED; St John Sutton M
    Geriatrics; 2003 Mar; 58(3):41-6; quiz 47. PubMed ID: 12650117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel pharmacological therapies for atrial fibrillation.
    Bagwe S; Leonardi M; Bissett J
    Curr Opin Cardiol; 2007 Sep; 22(5):450-7. PubMed ID: 17762547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertrophic cardiomyopathy.
    Sasson Z; Rakowski H; Wigle ED
    Cardiol Clin; 1988 May; 6(2):233-88. PubMed ID: 3066484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controversies in cardiovascular medicine. Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back for European patients.
    Maron BJ; Yacoub M; Dearani JA
    Eur Heart J; 2011 May; 32(9):1055-8. PubMed ID: 21324934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.
    Sherrid MV; Barac I; McKenna WJ; Elliott PM; Dickie S; Chojnowska L; Casey S; Maron BJ
    J Am Coll Cardiol; 2005 Apr; 45(8):1251-8. PubMed ID: 15837258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.